Are you a Health Professional? Jump over to the doctors only platform. Click Here

The Importance of Molecular Phenotype in Predicting Overall Survival in Patients with Relapsed or Primary Refractory DLBCL Treated with Second-Line Chemotherapy and ASCT- ASH Study

Print Friendly, PDF & Email

The American Society of Haematology (ASH) had its annual meeting earlier this month. Haematologists from around the world gathered at the San Diego Convention Centre to provide a forum for discussing critical issues in haematology. Nearly 20,000 clinicians, scientists, and others attended the four-day meeting, which consisted of an educational program and cutting-edge scientific sessions. The following was one of the presentations given at the meeting.

From 1993-2001, researchers from the Memorial Sloan Kettering Cancer Centre, NY, USA treated 186 patients with relapsed or primary refractory diffuse large B cell lymphoma (DLBCL) on IRB-approved clinical trials with ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy (SLT). Patients with chemosensitive disease received high dose chemoradiotherapy (HDT) and ASCT. In this context, patients achieving a complete response to ICE, pre-HDT/ASCT, have an improved overall survival (Journal of Clinical Oncology 1999, 12: 3776-85). Patients with chemosensitive primary refractory disease have the same overall survival as relapsed patients (Blood 2000, 96: 2399-2404); and the second-line age-adjusted IPI (SAAIPI) predicts overall survival (Blood 2003, 102: 1989-96). In an attempt to further delineate prognostic factors in this setting, tissue microarrays (TMA) were constructed as described in one of the researchers previous publications (Hum Pathol 2002: 968-74). All patients had a repeat biopsy prior to initiating SLT confirming active DLBCL; this sample was used for the TMA. Adequate tissue was available on 88 of these patients. TMA sections were stained for the following immunohistochemical markers and analyzed: MIB-1 (Ki-67), MUC1, MDR, p53, bcl-2, CD10, bcl-6, and MUM1. MIB-1 was scored in quartiles and for statistical purposes grouped as 1-2+ (<50% tumor cells positive) and 3-4+ (>50% tumor cells positive). For all other markers, a positive score was based on >20% of tumor cells staining positive. The “molecular phenotype”(MP), germinal center (GC) vs non-GC has an impact on progression-free survival in untreated DLBCL; researchers also evaluated whether the MP of the pre-ICE biopsy specimen could predict survival in patients with relapsed or primary refractory DLBCL undergoing SLT/HDT/ASCT. A GC phenotype is defined as either CD10 positive or bcl-6 positive and MUM 1 negative (Hans et al Blood 2004; 103: 275-282). At a median follow-up of 6.5 years the actuarial overall survival is 39.7% and 49% for patients receiving HDT/ASCT. In this subset of 88 Patients, researchers confirmed that the SAAIPI predicted outcome: good risk patients having an overall survival of 52% and poor risk 26%, p<0.001 and patients with primary refractory disease that received HDT/ASCT had the same overall survival as those with relapsed disease. None of the TMA markers impacted outcome; nor was there a difference in outcome based upon GC vs. non-GC TMA MP. The overall survival of GC Patients vs. non-GC Patients as analyzed by intent to treat is 38.3% and 42.9% respectively, p=0.7; and for the patients who received HDT/ASCT (53.4% vs. 54.5%, p=.97)Researchers concluded that a non-GC "molecular phenotype" does not predict for a poor outcome in patients with relapsed or primary refractory DLBCL treated with ICE-based SLT followed by HDT/ASCT.(Source: American Society of Haematology (ASH): Blood, Volume 104, issue 11, November 16, 2004.)

Print Friendly, PDF & Email


Posted On: 17 December, 2004
Modified On: 7 December, 2013


Created by: myVMC